Monitor for the actual Form 4 filing to confirm whether the sale was executed. A director/officer sale of this size (50k shares, ~$5.2M) at a $7.2B market cap is notable but not alarming on its own; watch for any pattern of additional insider selling or upcoming catalysts that could explain the timing.
RYTM drugs
RYTM drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 15 $96.77entry
- T+1 · 2mo ago +1.28%α +1.72% · $98.01
- T+5 · 8w ago +2.58%α +0.47% · $99.27
- T+20 · 5w ago −10.50%α −13.22% · $86.61
- T+44 · todayOpen
- T+60 · in 22d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
David Meeker, a director and officer of Rhythm Pharmaceuticals, filed a Form 144 notice of intent to sell 50,000 shares of common stock with an approximate market value of $5.24 million. The shares are to be sold through Morgan Stanley and were acquired via stock option exercise. This is a notable insider sale from a top executive at a $7.2B market cap biotech, though the filing is an advance notice of intent, not a completed transaction.
Key Facts
- David Meeker (Director and Officer) filed Form 144 to sell 50,000 shares.
- Estimated sale value: ~$5,235,500 based on filing date market price.
- Shares to be sold through Morgan Stanley Smith Barney LLC.
- Shares acquired via exercise of stock options on 09/14/2026.
- Filing date: 2026-09-14; proposed sale date also 09/14/2026.
Financial Impact
Proposed sale of 50,000 shares valued at approximately $5.24 million, representing about 0.07% of the company's $7.2B market cap.
Risk Factors
- Insider sale may signal reduced conviction ahead of a potential catalyst or earnings.
- Form 144 is only an intent to sell; the sale may not be executed.
- Stock option exercise and immediate sale could indicate tax planning rather than bearish view.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-009442 |
| Document: 0001950047-26-009442-index.html | 0001950047-26-009442 |
| Document: 0001950047-26-009442.txt | 0001950047-26-009442 |
Track record
26 reports on RYTM
9 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +32.06% at T+60 after the May 1, 2026 report. 10 of 13 went positive at some point.
Filters
- Nov 16, 2026today Press Release Bullish 5/10 Entry $107.48 Now $107.48 +0.00% settles Nov 24
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
- Nov 4, 202612d ago Press Release Bullish 5/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
- Nov 3, 202613d ago 8-K Bullish 6/10 No price data
- Nov 3, 202613d ago Press Release Bullish 6/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
- Nov 2, 202614d ago Press Release Neutral 5/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
- Oct 13, 20264w ago Press Release Bullish 6/10 Entry $86.71 to $88.62 Now $107.48 +23.95% ▲ +2.20% +1.75% vs SPY
- Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $86.61 to $90.20 Now $107.48 +24.10% ▲ +4.14% +5.30% vs SPY
- Sep 14, 20269w ago 144 Bearish 5/10 Viewing Entry $96.77 to $99.27 Now $107.48 −11.07% ▼ −2.58% −0.47% vs SPY
- Aug 17, 202613w ago Insider Cluster Bearish 6/10 Entry $115.25 to $113.35 Now $107.48 +6.74% ▲ +1.65% +1.45% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers